These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 29409610

  • 1. There and back again: An immunotherapy tale.
    Guo Y, Krupnick AS.
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
    [No Abstract] [Full Text] [Related]

  • 2. KEYNOTE-024: Unlocking a pathway to lung cancer cure?
    Rusch VW, Chaft J, Hellmann M.
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1777-1780. PubMed ID: 29395215
    [No Abstract] [Full Text] [Related]

  • 3. Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels.
    Sibille A, Henket M, Corhay JL, Louis R, Duysinx B.
    Acta Oncol; 2020 Mar; 59(3):257-259. PubMed ID: 31755328
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Immunotherapeutic approaches for small-cell lung cancer.
    Iams WT, Porter J, Horn L.
    Nat Rev Clin Oncol; 2020 May; 17(5):300-312. PubMed ID: 32055013
    [Abstract] [Full Text] [Related]

  • 8. Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer?
    Patel JD, Chmura SJ.
    Cancer; 2018 Jul 15; 124(14):2878-2880. PubMed ID: 29906817
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Finally, after decades, immune checkpoint inhibitors dethroned the standard of care of small-cell lung cancer.
    Saleh K, Khalife-Saleh N, Kourie HR.
    Immunotherapy; 2019 Apr 15; 11(6):457-460. PubMed ID: 30860440
    [No Abstract] [Full Text] [Related]

  • 11. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
    Vilariño N, Bruna J, Bosch-Barrera J, Valiente M, Nadal E.
    Cancer Treat Rev; 2020 Sep 15; 89():102067. PubMed ID: 32682248
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Role of immune-checkpoint inhibitors in lung cancer.
    Jain P, Jain C, Velcheti V.
    Ther Adv Respir Dis; 2018 Sep 15; 12():1753465817750075. PubMed ID: 29385894
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of immune checkpoint blockade for brain metastases.
    Harary M, Reardon DA, Iorgulescu JB.
    CNS Oncol; 2019 Jun 15; 8(2):CNS33. PubMed ID: 30854898
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
    Hoffner B, Leighl NB, Davies M.
    Cancer Treat Rev; 2020 Apr 15; 85():101979. PubMed ID: 32078962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.